These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 31616540)

  • 1. Using induced pluripotent stem cells for modeling Parkinson's disease.
    Ke M; Chong CM; Su H
    World J Stem Cells; 2019 Sep; 11(9):634-649. PubMed ID: 31616540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells.
    Stoddard-Bennett T; Reijo Pera R
    Cells; 2019 Jan; 8(1):. PubMed ID: 30621042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.
    Sison SL; Vermilyea SC; Emborg ME; Ebert AD
    Curr Neurol Neurosci Rep; 2018 Oct; 18(12):84. PubMed ID: 30284665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells.
    Li H; Jiang H; Zhang B; Feng J
    J Parkinsons Dis; 2018; 8(4):479-493. PubMed ID: 30149462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell Therapy for Parkinson's Disease.
    Shastry S; Hu J; Ying M; Mao X
    Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38139997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stemming the hype: what can we learn from iPSC models of Parkinson's disease and how can we learn it?
    Jacobs BM
    J Parkinsons Dis; 2014; 4(1):15-27. PubMed ID: 24398656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease.
    Chen W; Huang Q; Ma S; Li M
    ACS Chem Neurosci; 2019 Feb; 10(2):839-851. PubMed ID: 30346716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease.
    Chen LW; Kuang F; Wei LC; Ding YX; Yung KK; Chan YS
    CNS Neurol Disord Drug Targets; 2011 Jun; 10(4):449-58. PubMed ID: 21495962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Progress of Induced Pluripotent Stem Cells as Models of Parkinson's Disease.
    Kang JF; Tang BS; Guo JF
    Stem Cells Int; 2016; 2016():4126214. PubMed ID: 26880962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Cell Adhesion Molecules on the Neurite Outgrowth of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons.
    Peng SP; Schachner M; Boddeke E; Copray S
    Cell Reprogram; 2016 Apr; 18(2):55-66. PubMed ID: 26990843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding Parkinson's Disease through the Use of Cell Reprogramming.
    Playne R; Connor B
    Stem Cell Rev Rep; 2017 Apr; 13(2):151-169. PubMed ID: 28083784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using iPS Cells toward the Understanding of Parkinson's Disease.
    Torrent R; De Angelis Rigotti F; Dell'Era P; Memo M; Raya A; Consiglio A
    J Clin Med; 2015 Mar; 4(4):548-66. PubMed ID: 26239346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Approaches and Molecular Mechanisms for Directly Reprogramming Fibroblasts Into Neurons and Dopamine Neurons.
    Han F; Liu Y; Huang J; Zhang X; Wei C
    Front Aging Neurosci; 2021; 13():738529. PubMed ID: 34658841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of Naivetropic Induced Pluripotent Stem Cells from Parkinson's Disease Patients for High-Efficiency Genetic Manipulation and Disease Modeling.
    Hu Z; Pu J; Jiang H; Zhong P; Qiu J; Li F; Wang X; Zhang B; Yan Z; Feng J
    Stem Cells Dev; 2015 Nov; 24(21):2591-604. PubMed ID: 26218671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What we can learn from iPSC-derived cellular models of Parkinson's disease.
    Caiazza MC; Lang C; Wade-Martins R
    Prog Brain Res; 2020; 252():3-25. PubMed ID: 32247368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation and Characterization of Dopaminergic Neurons From Baboon Induced Pluripotent Stem Cells.
    Grow DA; Simmons DV; Gomez JA; Wanat MJ; McCarrey JR; Paladini CA; Navara CS
    Stem Cells Transl Med; 2016 Sep; 5(9):1133-44. PubMed ID: 27343168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies.
    Jung YW; Hysolli E; Kim KY; Tanaka Y; Park IH
    Curr Opin Neurol; 2012 Apr; 25(2):125-30. PubMed ID: 22357218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea Facilitates Manifestation of Disease Relevant Phenotypes in Patients-Derived IPSCs-Based Modeling of Late-Onset Parkinson's Disease.
    Tan Y; Ke M; Huang Z; Chong CM; Cen X; Lu JH; Yao X; Qin D; Su H
    Aging Dis; 2019 Oct; 10(5):1037-1048. PubMed ID: 31595201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling Parkinson's Disease: iPSCs towards Better Understanding of Human Pathology.
    Avazzadeh S; Baena JM; Keighron C; Feller-Sanchez Y; Quinlan LR
    Brain Sci; 2021 Mar; 11(3):. PubMed ID: 33799491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solving the puzzle of Parkinson's disease using induced pluripotent stem cells.
    Zhao P; Luo Z; Tian W; Yang J; Ibáñez DP; Huang Z; Tortorella MD; Esteban MA; Fan W
    Exp Biol Med (Maywood); 2014 Nov; 239(11):1421-32. PubMed ID: 24939824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.